[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
July 1989

Safety of Intrathecal Steroids in Multiple Sclerosis-Reply

Author Affiliations

48 Omega Dr Omega Professional Center Newark, DE 19713

Arch Neurol. 1989;46(7):718-719. doi:10.1001/archneur.1989.00520430012004

In Reply.  —Between 1960 and 1962, six studies performed on more than 5000 patients reported sanguine results from the intrathecal use of methylprednisolone acetate (Depo-Medrol).1 Numerous regimens were tried. Sehgal and Gardner2 advocated it after treating 3000 patients for "failed disk syndrome," arachnoiditis, cluster headache, pseudotumor cerebri, plexitis, Guillain-Barré syndrome, and multiple sclerosis. Only minor side effects were mentioned and the steroid was reported uniformly helpful. These authors mentioned six negative autopsy reports in a two-sentence description, and no details were given. Boines3 simultaneously tested the compound on more than 2000 patients with multiple sclerosis and reported improvement from 75% to 90%, regardless of the stage of the disease; spasticity was stated to have been relieved, even in patients with chronic disease.Between 1964 and 1969, three authors4-6 attempted to treat spasticity in multiple sclerosis and other diseases by a variety of regimens, and their results were poor.